The biopharmaceutical company has attained an elite worldwide license to several patents from the nonprofit Research Development Foundation (RDF), and the company develops gene therapy treatments for congestive heart failure and other chronic diseases. Along with group of patents, Renova Therapeutics’ has expanded its portfolio in the cardiovascular and metabolic disease space, thus imparting future road for its­ paracrine gene therapy product pipeline [more]